Antibody avidity measurements in recipients of Cervarix® vaccine following a two-dose schedule or a three-dose schedule

Vaccine

Volumn 32, Issue 26, 2014, Pages 3232-3236

  Boxus, Mathieu ^a   Lockman, Laurence ^a   Fochesato, Michel ^a   Lorin, Clarisse ^a   Thomas, Florence ^a   Giannini, Sandra L ^a  

^a GSK   (Belgium)

Author keywords

Antibodies; Avidity; Cervical cancer; Human papillomavirus; Vaccine

Indexed keywords

WART VIRUS VACCINE;

ADOLESCENT; ADULT; ANTIBODY BLOOD LEVEL; ANTIBODY RESPONSE; ANTIGEN BINDING; ANTIGEN SPECIFICITY; ARTICLE; BINDING AFFINITY; BLOOD SAMPLING; CANCER PREVENTION; CHILD; CLINICAL TRIAL; CLINICAL TRIAL (TOPIC); DOSAGE SCHEDULE COMPARISON; DRUG DOSE REGIMEN; ENZYME LINKED IMMUNOSORBENT ASSAY; FEASIBILITY STUDY; FEMALE; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; NORMAL HUMAN; PRIORITY JOURNAL; UTERINE CERVIX CANCER; VACCINATION;

ANTIBODIES; AVIDITY; CERVICAL CANCER; HUMAN PAPILLOMAVIRUS; VACCINE;

ADOLESCENT; ADULT; ANTIBODIES, VIRAL; ANTIBODY AFFINITY; CHILD; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; IMMUNIZATION SCHEDULE; MIDDLE AGED; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; UTERINE CERVICAL NEOPLASMS; VACCINES, VIRUS-LIKE PARTICLE; YOUNG ADULT;

EID: 84900447648     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2014.04.005     Document Type: Article

References (33)

1. zur Hausen H. Papillomaviruses in the causation of human cancers-a brief historical account. Virology 2009, 384:260-265.
2. Smith J.S., Lindsay L., Hoots B., Keys J., Franceschi S., Winer R., et al. Human papillomavirus type distribution in invasive cervical cancer and high-grade cervical lesions: a meta-analysis update. Int J Cancer 2007, 121:621-632.
3. Lehtinen M., Paavonen J., Wheeler C.M., Jaisamrarn U., Garland S.M., Castellsague X., et al. Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial. Lancet Oncol 2012, 13:89-99.
4. Malagón T., Drolet M., Boily M.C., Franco E.L., Jit M., Brisson J., et al. Cross-protective efficacy of two human papillomavirus vaccines: a systematic review and meta-analysis. Lancet Infect Dis 2012, 12:781-789.
5. Pedersen C., Petaja T., Strauss G., Rumke H.C., Poder A., Richardus J.H., et al. Immunization of early adolescent females with human papillomavirus type 16 and 18 L1 virus-like particle vaccine containing AS04 adjuvant. J Adolesc Health 2007, 40:564-571.
6. Romanowski B., Schwarz T.F., Ferguson L.M., Peters K., Dionne M., Schulze K., et al. Immunogenicity and safety of the HPV-16/18 AS04-adjuvanted vaccine administered as a 2-dose schedule compared with the licensed 3-dose schedule: results from a randomized study. Hum Vaccin 2011, 7:1374-1386.
7. Stanley M., Pinto L.A., Trimble C. Human papillomavirus vaccines-immune responses. Vaccine 2012, 30(Suppl 5):F83-F87.
8. Schwarz T.F., Leo O. Immune response to human papillomavirus after prophylactic vaccination with AS04-adjuvanted HPV-16/18 vaccine: improving upon nature. Gynecol Oncol 2008, 110:S1-S10.
9. Kemp T.J., García-Piñeres A., Falk R.T., Poncelet S., Dessy F., Giannini S.L., et al. Evaluation of systemic and mucosal anti-HPV16 and anti-HPV18 antibody responses from vaccinated women. Vaccine 2008, 26:3608-3616.
10. ®. Vaccine 2012, 31:165-170.
11. Giannini S.L., Hanon E., Moris P., Van Mechelen M., Morel S., Dessy F., et al. Enhanced humoral and memory B cellular immunity using HPV16/18 L1 VLP vaccine formulated with the MPL/aluminium salt combination (AS04) compared to aluminium salt only. Vaccine 2006, 24:5937-5949.
12. McHeyzer-Williams L.J., McHeyzer-Williams M.G. Antigen-specific memory B cell development. Annu Rev Immunol 2005, 23:487-513.
13. Vinuesa C.G., Tangye S.G., Moser B., Mackay C.R. Follicular B helper T cells in antibody responses and autoimmunity. Nat Rev Immunol 2005, 5:853-865.
14. Pelletier N., McHeyzer-Williams L.J., Wong K.A., Urich E., Fazilleau N., McHeyzer-Williams M.G. Plasma cells negatively regulate the follicular helper T cell program. Nat Immunol 2010, 11:1110-1118.
15. Khurana S., Wu J., Dimitrova M., King L.R., Manischewitz J., Graham B.S., et al. DNA priming prior to inactivated influenza A(H5N1) vaccination expands the antibody epitope repertoire and increases affinity maturation in a boost-interval-dependent manner in adults. J Infect Dis 2013, 208:413-417.
16. Schlesinger Y., Granoff D.M. Avidity and bactericidal activity of antibody elicited by different Haemophilus influenzae type b conjugate vaccines. The Vaccine Study Group. JAMA 1992, 267:1489-1494.
17. Denoël P.A., Goldblatt D., de Vleeschauwer I., Jacquet J.M., Pichichero M.E., Poolman J.T. Quality of the Haemophilus influenzae type b (Hib) antibody response induced by diphtheria-tetanus-acellular pertussis/Hib combination vaccines. Clin Vaccine Immunol 2007, 14:1362-1369.
18. Anttila M., Eskola J., Åhman H., Käyhty H. Avidity of IgG for Streptococcus pneumoniae type 6B and 23F polysaccharides in infants primed with pneumococcal conjugates and boosted with polysaccharide or conjugate vaccines. J Infect Dis 1998, 177:1614-1621.
19. Safaeian M., Kemp T.J., Pan D.Y., Porras C., Rodriguez A.C., Schiffman M., et al. Cross-protective vaccine efficacy of the bivalent HPV vaccine against HPV31 is associated with humoral immune responses: Results from the Costa Rica Vaccine Trial. Hum Vaccine Immunother 2013, 9:1399-1406.
20. Dauner J.G., Pan Y., Hildesheim A., Harro C., Pinto L.A. Characterization of the HPV-specific memory B cell and systemic antibody responses in women receiving an unadjuvanted HPV16 L1 VLP vaccine. Vaccine 2010, 28:5407-5413.
21. Peled J.U., Kuang F.L., Iglesias-Ussel M.D., Roa S., Kalis S.L., Goodman M.F., et al. The biochemistry of somatic hypermutation. Annu Rev Immunol 2008, 26:481-511.
22. Hangartner L., Zinkernagel R.M., Hengartner H. Antiviral antibody responses: the two extremes of a wide spectrum. Nat Rev Immunol 2006, 6:231-243.
23. Kreimer A.R., Rodriguez A.C., Hildesheim A., Herrero R., Porras C., Schiffman M., et al. Proof-of-principle evaluation of the efficacy of fewer than three doses of a bivalent HPV16/18 vaccine. J Natl Cancer Inst 2011, 103:1444-1451.
24. Rivera Medina D.M., Valencia A., de Velasquez A., Huang L.M., Prymula R., García-Sicilia J., et al. Safety and immunogenicity of the HPV-16/18 AS04-adjuvanted vaccine: a randomized, controlled trial in adolescent girls. J Adolesc Health 2010, 46:414-421.
25. Schwarz T.F., Spaczynski M., Schneider A., Wysocki J., Galaj A., Perona P., et al. Immunogenicity and tolerability of an HPV-16/18 AS04-adjuvanted prophylactic cervical cancer vaccine in women aged 15-55 years. Vaccine 2009, 27:581-587.
26. Christensen N.D., Dillner J., Eklund C., Carter J.J., Wipf G.C., Reed C.A., et al. Surface conformational and linear epitopes on HPV-16 and HPV-18 L1 virus-like particles as defined by monoclonal antibodies. Virology 1996, 223:174-184.
27. Brown D.R., Kjaer S.K., Sigurdsson K., Iversen O.E., Hernandez-Avila M., Wheeler C.M., et al. The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in generally HPV-naive women aged 16-26 years. J Infect Dis 2009, 199:926-935.
28. Russell F.M., Balloch A., Licciardi P.V., Carapetis J.R., Tikoduadua L., Waqatakirewa L., et al. Serotype-specific avidity is achieved following a single dose of the 7-valent pneumococcal conjugate vaccine, and is enhanced by 23-valent pneumococcal polysaccharide booster at 12 months. Vaccine 2011, 29:4499-4506.
29. Dauner J.G., Pan Y., Hildesheim A., Kemp T.J., Porras C., Pinto L.A. Development and application of a GuHCl-modified ELISA to measure the avidity of anti-HPV L1 VLP antibodies in vaccinated individuals. Mol Cell Probes 2012, 26:73-80.
30. Romero-Steiner S., Holder P.F., Gomez de Leon P., Spear W., Hennessy T.W., Carlone G.M. Avidity determinations for Haemophilus influenzae Type b anti-polyribosylribitol phosphate antibodies. Clin Diagn Lab Immunol 2005, 12:1029-1035.
31. McHeyzer-Williams L.J., Pelletier N., Mark L., Fazilleau N., McHeyzer-Williams M.G. Follicular helper T cells as cognate regulators of B cell immunity. Curr Opin Immunol 2009, 21:266-273.
32. Einstein M.H., Baron M., Levin M.J., Chatterjee A., Fox B., Scholar S., et al. Comparative immunogenicity and safety of human papillomavirus (HPV)-16/18 vaccine and HPV-6/11/16/18 vaccine: follow-up from months 12-24 in a Phase III randomized study of healthy women aged 18-45 years. Hum Vaccin 2011, 7:1343-1358.
33. ® human papillomavirus (HPV) cervical cancer vaccines in healthy women aged 18-45 years. Hum Vaccin 2009, 5:705-719.